Bbojitm thermofirm bee gynecomastia oil is one of many topical products marketed online claiming to reduce male breast enlargement, yet the clinical evidence supporting such products is absent. Gynaecomastia — the benign enlargement of glandular breast tissue in males — is a common condition with a range of hormonal, medicinal, and lifestyle causes. Before reaching for an unregulated topical oil or cream, it is essential to understand what gynaecomastia actually is, why these products are unlikely to work, what safety risks they may carry, and what NHS-recommended treatments are genuinely available.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an imbalance between oestrogen and androgen activity; causes include puberty, medications, hormonal disorders, and recreational substances.

Have any more questions about this? Message our pharmaceutical team to get more info →

Gynaecomastia is the benign enlargement of glandular breast tissue in males, resulting in a firm or rubbery swelling beneath one or both nipples. It is distinct from pseudogynaecomastia, which refers to fatty tissue accumulation in the chest area without true glandular growth. The condition is relatively common and can affect males at any age, from newborns to older adults.

The underlying cause is typically an imbalance between oestrogen and androgen (testosterone) activity in breast tissue. This imbalance can arise from a wide range of factors, including:

• Puberty – the most common cause in adolescent males, usually resolving within one to two years

• Hormonal conditions – such as hypogonadism, hyperthyroidism, hyperprolactinaemia, or adrenal disorders

• Chromosomal conditions – including Klinefelter's syndrome (47,XXY), which is associated with reduced androgen production

• Testicular or germ-cell tumours – hCG-secreting tumours can stimulate oestrogen production and cause gynaecomastia; this is an important cause to exclude

• Medications – including spironolactone, cimetidine, finasteride, antiandrogens, anabolic steroids, some antipsychotics, certain SSRIs, and some antiretroviral medicines

• Recreational substances – cannabis, alcohol, and anabolic steroids are well-documented contributors

• Liver disease or chronic kidney disease – which can alter hormone metabolism

• Idiopathic causes – in many adult cases, no specific cause is identified

It is important to distinguish gynaecomastia from male breast cancer, which, although rare, can present similarly. Any unilateral, hard, irregular, or rapidly growing lump — or one associated with nipple discharge, skin changes, or axillary lymph node swelling — warrants prompt medical assessment. Understanding the root cause is essential before considering any form of treatment, as addressing the underlying condition — for example, stopping a causative medication — may resolve the enlargement without further intervention.

Further information: NICE CKS: Gynaecomastia; NHS: Gynaecomastia (breast enlargement in men).

Topical Oils and Creams Marketed for Gynaecomastia

Topical products such as thermofirm or bee gynecomastia oils are marketed with claims of firming or reducing chest tissue, but lack peer-reviewed evidence and are not licensed medicines in the UK.

A growing number of topical products are marketed online and through social media platforms claiming to reduce or eliminate gynaecomastia. These include oils, creams, gels, and serums, often branded with terms such as 'thermofirm', 'firming', 'fat-burning', or 'chest-sculpting'. Products associated with search terms such as 'bbojitm thermofirm bee gynecomastia oil' fall into this category — typically sold as natural or herbal formulations purporting to firm chest tissue or reduce glandular swelling.

These products commonly contain ingredients such as:

• Essential oils – including eucalyptus, peppermint, or tea tree oil

• Plant extracts – such as green tea, turmeric, or ginger

• Bee-derived ingredients – including beeswax, bee venom, or propolis, which are sometimes marketed for their supposed anti-inflammatory properties

• Caffeine or retinol – ingredients borrowed from cosmetic cellulite or skin-firming products

Manufacturers often claim these ingredients stimulate localised fat breakdown (lipolysis), tighten skin, or reduce inflammation in breast tissue. These claims are typically presented without peer-reviewed clinical evidence and are frequently accompanied by before-and-after photographs or anecdotal testimonials rather than controlled trial data.

It is worth noting that the skin acts as a significant barrier to the absorption of most topically applied compounds. For most consumer-grade cosmetic formulations, achieving clinically meaningful concentrations in deep glandular breast tissue through topical application alone is unlikely. This is in contrast to purpose-designed, licensed transdermal medicines (such as hormone patches or gels), which use specific pharmaceutical vehicles and delivery systems, are subject to rigorous clinical testing, and hold a UK marketing authorisation. Consumer topical products marketed for gynaecomastia are not in this category.

Further information: MHRA: Is your product a medicine? (borderline products guidance).

Is There Any Clinical Evidence These Products Work?

There is no robust clinical evidence from controlled trials that any topical oil or cream reduces true gynaecomastia; some 'natural' ingredients such as lavender and tea tree oil may even worsen the condition.

To date, there is no robust clinical evidence from peer-reviewed, controlled trials demonstrating that any topical oil, cream, or gel — including products marketed under names such as 'thermofirm' or 'bee gynaecomastia oil' — is effective in reducing true gynaecomastia. The absence of such evidence is significant, as gynaecomastia involves proliferation of glandular ductal tissue, which is not amenable to topical fat-reduction strategies.

Some individual ingredients found in these products have been studied in other contexts. For example:

• Caffeine has been investigated in topical formulations for cellulite, with modest and inconsistent results in adipose tissue — not glandular tissue

• Bee venom has been explored in small studies for anti-inflammatory and skin-tightening effects, but no credible evidence supports its use in gynaecomastia

• Plant-based compounds with oestrogenic or anti-androgenic activity – compounds found in lavender and tea tree oil have been associated in published case reports with the development of gynaecomastia in prepubertal boys, rather than its resolution. These reports suggest that some 'natural' ingredients may potentially worsen the condition

It is also important to recognise that pseudogynaecomastia — fatty chest enlargement without glandular involvement — may appear to respond to weight loss or body composition changes, which could be misattributed to a topical product. This creates a misleading impression of efficacy.

Healthcare professionals and patients should be cautious about interpreting testimonials or social media reviews as evidence of effectiveness. Regulatory bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) require rigorous clinical trial data before any medicinal claim can be made about a product. Products making therapeutic claims without such evidence may be operating outside the law.

Further information: NICE CKS: Gynaecomastia; MHRA: Is your product a medicine?

Safety Concerns and MHRA Guidance on Unregulated Products

Unregulated topical gynaecomastia products carry risks including allergic reactions, anaphylaxis from bee-derived ingredients, hormonal disruption, and delayed diagnosis of an underlying condition.

The MHRA is responsible for regulating medicines and medical devices in the United Kingdom. Products that make medicinal claims — such as treating, reducing, or curing gynaecomastia — are legally required to hold a UK marketing authorisation (product licence, identified by a 'PL' number) unless they are classified purely as cosmetics. Many topical products sold online for gynaecomastia occupy a regulatory grey area, making claims that imply medicinal benefit whilst being sold as cosmetics or food supplements to avoid regulatory scrutiny.

Key safety concerns associated with unregulated topical products include:

• Undisclosed or unlicensed active ingredients – some products have been found to contain pharmaceutical compounds not listed on the label

• Allergic reactions and contact dermatitis – particularly with bee-derived ingredients, essential oils, and plant extracts, which carry a risk of sensitisation

• Systemic allergic reactions and anaphylaxis – bee-derived ingredients (including bee venom and propolis) carry a risk of serious systemic allergic reactions, including anaphylaxis. Individuals with a known allergy to bee products should avoid these products entirely. If any systemic symptoms occur after use — such as swelling of the face or throat, difficulty breathing, rapid heartbeat, or dizziness — seek emergency medical help immediately (call 999)

• Hormonal disruption – certain plant extracts (e.g., lavender, tea tree) contain compounds with weak oestrogenic activity, which could theoretically worsen gynaecomastia

• Delayed diagnosis – using unproven products may delay individuals from seeking appropriate medical assessment, potentially allowing an underlying condition to progress

The MHRA advises consumers to be wary of products sold online that make exaggerated health claims, particularly those without a valid UK marketing authorisation (PL number). Purchasing products from unverified online retailers also carries the risk of receiving counterfeit or contaminated goods.

If you experience a suspected side effect or adverse reaction from any product, or wish to report a suspected counterfeit or unlicensed product, you can do so via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. When in doubt, consulting a pharmacist or GP before using any such product is strongly advisable.

Further information: MHRA Yellow Card scheme; MHRA: Is your product a medicine? (borderline products guidance).

NHS-Recommended Treatments for Gynaecomastia

NHS management focuses on treating the underlying cause; persistent cases may be treated with specialist-supervised off-label medicines such as tamoxifen, or referred for surgical intervention.

The NHS approach to gynaecomastia is guided by identifying and addressing the underlying cause wherever possible. In many cases — particularly in adolescent males — the condition resolves spontaneously without any specific treatment. Reassurance and monitoring are therefore the first-line approach in physiological gynaecomastia.

Where an underlying cause is identified, management focuses on that condition directly. For example:

• Medication review – if a prescribed drug is identified as the cause, a clinician may consider switching to an alternative where clinically appropriate

• Lifestyle modification – reducing alcohol intake, stopping anabolic steroid use, and achieving a healthy body weight can be beneficial

• Hormonal investigation and treatment – if a hormonal disorder is identified, appropriate endocrine management may be initiated

For persistent or symptomatic gynaecomastia that does not resolve with conservative measures, pharmacological treatment may be considered by a specialist. The medicines used are prescribed off-label (i.e., outside their licensed indications) and are generally most effective in early, tender gynaecomastia rather than established, fibrous disease:

• Tamoxifen – a selective oestrogen receptor modulator (SERM) that blocks oestrogen activity in breast tissue. It is the most commonly used off-label option and has the best evidence base for gynaecomastia. Typical off-label use is 10–20 mg daily for three to six months, initiated and supervised by a specialist. Important adverse effects include an increased risk of venous thromboembolism (VTE), hot flushes, and, rarely, endometrial changes; a full risk assessment should be undertaken before prescribing

• Raloxifene – another SERM used off-label in some cases, particularly pubertal or idiopathic gynaecomastia, with a similar mechanism to tamoxifen. Evidence is limited but suggests comparable or modest benefit in some studies; VTE risk applies similarly

• Anastrozole – an aromatase inhibitor that reduces oestrogen production. Its role is limited; evidence from controlled trials is inconsistent, and it is not generally considered first-line for idiopathic adult gynaecomastia. It may be considered in selected cases under specialist supervision

For established, fibrous gynaecomastia that has been present for more than one to two years, medical therapy is generally less effective, and surgical intervention (subcutaneous mastectomy or liposuction) may be considered. Referral to an endocrinologist or breast surgeon via the NHS is the appropriate pathway for persistent or distressing cases. NICE does not currently have a specific guideline on gynaecomastia, but NICE CKS provides primary care guidance on assessment and management.

Further information: NICE CKS: Gynaecomastia; BNF: Tamoxifen, Anastrozole, Raloxifene; emc SmPC: Tamoxifen, Anastrozole; NHS: Gynaecomastia treatment.

When to Speak to a GP About Gynaecomastia

You should see a GP promptly if you notice a hard, irregular, or rapidly growing breast lump, nipple discharge, or skin changes, as these features require urgent assessment to exclude malignancy.

Many men and adolescents feel embarrassed about gynaecomastia and may turn to online products before seeking medical advice. However, there are several circumstances in which speaking to a GP promptly is important, both for accurate diagnosis and to rule out more serious underlying conditions.

You should contact your GP if you notice:

• A new or growing lump in one or both breasts

• Breast swelling that is hard, irregular, or fixed to surrounding tissue

• Nipple discharge, skin changes, or nipple inversion

• Swelling of the axillary (armpit) lymph nodes

• Breast pain or tenderness that is persistent or worsening

• Swelling that develops rapidly or is associated with other symptoms such as fatigue, unexplained weight loss, or testicular changes

• Gynaecomastia that persists beyond two years in an adolescent, or develops in an adult without an obvious cause

Urgent referral: In line with NICE guidance on suspected cancer (NICE NG12), GPs should refer urgently (via the two-week-wait pathway) any male aged 30 years or over with an unexplained breast lump, with or without pain. Males aged 50 or over with unilateral nipple discharge, nipple retraction, or other concerning changes should also be referred urgently. If you have any of these features, ask your GP about an urgent referral.

A GP will typically take a thorough history, including medication and substance use, and may arrange blood tests to assess hormone levels (including testosterone, LH, FSH, oestradiol, prolactin, and thyroid function) and liver and kidney function. Where a testicular tumour or malignancy is suspected, targeted tests such as beta-hCG and oestradiol may be requested, along with imaging such as testicular ultrasound or mammography, depending on clinical findings. Routine non-specific tumour markers are not generally recommended in primary care without clinical indication.

It is also worth raising the topic with a GP before using any topical product marketed for gynaecomastia. A clinician can help determine whether the swelling is true gynaecomastia or pseudogynaecomastia, identify any treatable cause, and advise on evidence-based management options. Self-treating with unregulated products not only risks delaying appropriate care but may also introduce unnecessary safety risks. Open, non-judgemental conversations with a GP remain the safest and most effective starting point.

Further information: NICE NG12: Suspected cancer: recognition and referral; NICE CKS: Gynaecomastia; NHS: Gynaecomastia.

Frequently Asked Questions